Sudeep Pharma Limited — PPTs, 21-05-2026: Investor Presentation

Here's a retail-investor-friendly summary of the Sudeep Pharma presentation:

**Business Performance:** Sudeep Pharma reported a strong FY26 with a record revenue of ₹642.3 Cr, up 28% YoY. Q4 FY26 revenue also grew 16% YoY to ₹182.3 Cr. This growth was driven by healthy demand across verticals and contributions from the acquired NSS business, despite temporary raw material price hikes and supply chain disruptions.

**Growth Drivers or Strategy:** Key focus areas include expanding advanced formulation capabilities via the NSS acquisition, particularly in Europe, and developing the new Battery Materials business. Groundbreaking for the Dahej Battery Materials plant has occurred, targeting LFP battery-grade iron phosphate production.

**Recent Developments:** Sudeep Pharma acquired an 85% stake in Nutrition Supplies Services (NSS), integrating its capabilities and European market presence. Construction has begun on the Dahej Battery Materials facility, and the company received qualification orders from Korean customers and a significant purchase order from an Indian player for battery chemicals.

**Key Financial Metrics:** FY26 Revenue: ₹642.3 Cr (+28% YoY). FY26 PAT: ₹174.3 Cr (+26% YoY). EPS: ₹15.50 (+21% YoY).

**Management Commentary / Outlook:** Management is confident in the long-term growth trajectory, citing expanding global reach, customer engagement, and strategic investments in Specialty Ingredients and Battery Materials. They anticipate benefits from recent price revisions to reflect in upcoming quarters.